Country: Canada
Language: English
Source: Health Canada
SUNITINIB (SUNITINIB MALATE)
TARO PHARMACEUTICALS INC
L01EX01
SUNITINIB
37.5MG
CAPSULE
SUNITINIB (SUNITINIB MALATE) 37.5MG
ORAL
100
Prescription
Active ingredient group (AIG) number: 0151642004; AHFS:
APPROVED
2022-01-07
_Pr_ _TARO-SUNITINIB Product Monograph _ _ Page 1 of 65_ PRODUCT MONOGRAPH PR TARO-SUNITINIB Sunitinib Capsules 12.5 mg, 25 mg, 37.5 mg, 50 mg sunitinib per capsule (as sunitinib malate) Tyrosine Kinase Inhibitor, Anti-Tumour Agent Taro Pharmaceuticals Inc. 130 East Drive Brampton, ON L6T 1C1 Date of Preparation: January 5, 2022 Submission Control No.: 235867 _Pr_ _TARO-SUNITINIB Product Monograph _ _ _ _ _ _ _ _ _ _ _ _ _ _Page 2 of 65 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION....................................................... 3 SUMMARY PRODUCT INFORMATION ......................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................................... 3 CONTRAINDICATIONS .................................................................................................... 4 WARNINGS AND PRECAUTIONS.................................................................................... 4 ADVERSE REACTIONS....................................................................................................15 DRUG INTERACTIONS ....................................................................................................30 DOSAGE AND ADMINISTRATION .................................................................................31 OVERDOSAGE ..................................................................................................................32 ACTION AND CLINICAL PHARMACOLOGY...............................................................32 STORAGE AND STABILITY ............................................................................................36 SPECIAL HANDLING INSTRUCTIONS..........................................................................36 DOSAGE FORMS, COMPOSITION AND PACKAGING ................................................36 PART II: SCIENTIFIC INFORMATION .............................................................................37 PHARMACEUTICAL INFORMATION ............. Read the complete document